CASE REPORTSTopiramate plus paroxetine in treatment-resistant obsessive–compulsive disorderHollander, Eric; Dell'Osso, BernardoAuthor Information Department of Psychiatry, Compulsive, Impulsive and Anxiety Disorders Program, Mount Sinai School of Medicine, New York, New York, USA Correspondence and requests for reprints to Dr Bernardo Dell'Osso, Compulsive, Impulsive and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, Box 1230, One Gustave L. Levy Place, New York, NY 10029, USA Tel: +1 212 2413623; fax: +1 212 9874031; e-mail: [email protected] Conflict of interest: Professor E. Hollander is on the advisory board of Abbott, Ortho-McNeil and Solvay. Dr B. Dell'Osso does not have any affiliation or financial interest in any organization that might pose a conflict of interest. Received 23 November 2005 Accepted 6 December 2005 International Clinical Psychopharmacology: May 2006 - Volume 21 - Issue 3 - p 189-191 doi: 10.1097/01.yic.0000199453.54799.cc Buy Metrics Abstract We report a case of treatment-resistant obsessive–compulsive disorder (OCD) that was successfully treated with a pharmacological augmentation of topiramate plus paroxetine. The patient, a 45-year-old woman, was on a stable dose of paroxetine (40 mg/day) when she was started on topiramate (up to 150 mg/day). After 9 weeks of this treatment, her clinical condition remarkably improved, as indicated by a significant decrease of the evaluation scales (Yale–Brown Obsessive–Compulsive Scale and Clinical Global Impression Scale). Our case suggests that topiramate might be beneficial in augmentation with selective serotonin reuptake inhibitors in patients with treatment-resistant OCD, although further investigations are warranted to confirm our findings. © 2006 Lippincott Williams & Wilkins, Inc.